The association of diabetic microvascular and macrovascular disease with cutaneous circulation in patients with type 2 diabetes mellitus

2019 ◽  
Vol 33 (2) ◽  
pp. 165-170 ◽  
Author(s):  
Ioanna Eleftheriadou ◽  
Anastasios Tentolouris ◽  
Pinelopi Grigoropoulou ◽  
Dimitrios Tsilingiris ◽  
Ioanna Anastasiou ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Macrovascular Disease ◽  
Cutaneous Circulation

scholarly journals Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus

2009 ◽  
Vol 169 (6) ◽  
pp. 616 ◽  
Author(s):  
Adriaan Kooy ◽  
Jolien de Jager ◽  
Philippe Lehert ◽  
Daniël Bets ◽  
Michiel G. Wulffelé ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Macrovascular Disease ◽  
Long Term Effects

Predictors of Macrovascular Disease in Patients With Type 2 Diabetes Mellitus

2001 ◽  
Vol 76 (7) ◽  
pp. 707-712 ◽  
Author(s):  
Haitham S. Abu-Lebdeh ◽  
David O. Hodge ◽  
Tu T. Nguyen
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Macrovascular Disease

Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus

Cardiology ◽  
2016 ◽  
Vol 135 (2) ◽  
pp. 108-126
Author(s):  
Karan Kapoor ◽  
Praveen George ◽  
Michael Miller
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Disease Risk ◽  
Macrovascular Disease ◽  
Cardiovascular Outcomes ◽  
Significant Shift ◽  
Glucose Lowering ◽  
Dipeptidyl Peptidase 4 Inhibitors

Objectives: To review the spectrum of contemporary cardiovascular outcomes trials (CVOTS) in type 2 diabetes mellitus (T2DM), spanning both the pre- and post-ACCORD eras. Methods: We reviewed a total of 12 CVOTs and delineated the two eras in accordance with the 2008 US Food and Drug Administration (FDA) mandate requiring completion of CVOTs prior the licensing of new glucose-lowering agents. The salient implications regarding macrovascular disease complications were summarized. Results: Five trials in the pre-ACCORD and 7 in the post-ACCORD era were identified. Heterogeneous results pertaining to the degree of glycemic control associated with optimal macrovascular disease risk reduction, as well as the safest pharmacologic means to do so, were observed. Conclusions: The post-ACCORD era is representative of a significant shift in the landscape of CVOTs in T2DM, with an emphasis on safety of glucose-lowering agents. Recently completed and ongoing trials of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors will continue to inform clinical practice on safe and effective ways to reduce CV risk in T2DM.

Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus

2011 ◽  
Vol 91 (1) ◽  
pp. e11-e14 ◽  
Author(s):  
Sang Youl Rhee ◽  
Young Seol Kim ◽  
Suk Chon ◽  
Seungjoon Oh ◽  
Jeong-taek Woo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Macrovascular Disease ◽  
Long Term Effects
Sign in / Sign up

Export Citation Format

Share Document